Jazz Pharmaceuticals’ Zepzelca combination meets endpoints in lung cancer trial

Jazz Pharmaceuticals announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca in combination with the PD-L1 inhibitor atezolizumab – Tecentriq- compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage small cell lung cancer, or ES-SCLC, following induction therapy with carboplatin, etoposide and atezolizumab. The combination of Zepzelca and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival and progression-free survival, compared to treatment with atezolizumab alone. The combination was generally well-tolerated. The preliminary safety data in the ongoing trial was consistent with the known safety profiles of Zepzelca and atezolizumab with no new safety signals observed in the combination arm. The company plans to submit an sNDA in the first half of 2025 to support this combination in the first-line maintenance setting for ES-SCLC.